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ABSTRACT
We use a data driven approach on a cleaned adverse drug reaction database to
determine the reaction severity of several covid-19 drug combinations currently
under investigation. We further examine their safety for vulnerable populations
such as individuals 65 years and older. Our key findings include 1.
hydroxychloroquine/chloroquine are associated with increased adverse drug event
severity versus other drug combinations already not recommended by NIH
treatment guidelines, 2. hydroxychloroquine/azithromycin are associated with
lower adverse drug event severity among older populations, 3. lopinavir/ritonavir
had lower adverse reaction severity among toddlers and 4. the combination of
azithromycin, hydroxychloroquine and tocilizumab is safer than its component
drugs. While our approach does not consider drug efficacy, it can help prioritize
clinical trials for drug combinations by focusing on those with the lowest reaction
severity and thus increase potential treatment options for covid-19 patients.
Keywords: SARS-CoV-2, Adverse Drug Events, FDA FAERS, TylerADE
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INTRODUCTION
While the SARS-CoV-2 global pandemic brought much attention to the discovery
of a vaccine, the use of existing medication to reduce respiratory infection and
alleviate patient symptoms is equally important. So far there has been no safe and
effective treatment for the virus. Several medicines have received high-profile
attention such as the anti-malarial drugs hydroxychloroquine/chloroquine which
shown early evidence of effective prevention (Liu et al., 2020), and further clinical
studies finding hydroxychloroquine more effective than chloroquine (Fantini et al.,
2020). Hydroxychloroquine has been found useful for suppressing the cytokine
storm in late stages of infection, but not effective in inhibiting the early onset stages
(Yao et al., 2020). Interest has also increased for the drug combination of
hydroxychloroquine/azithromycin after US President Donald Trump tweeted that
the combination was one of “the biggest game changers in the history of medicine”
(Trump, 2020). His tweet cited a small French study of 36 patients that had
encouraging results (Gautret et al., 2020). However, treatment guidelines from the
National Institutes of Health (NIH) recommended against their use because of
potential toxicity (National Institutes of Health, 2020).
NIH further recommended against the use of lopinavir/ritonavir because of negative
clinical trial data and has recommended against the use of interferons and janus
kinase inhibitors. Besides insufficient clinical data to either recommend for or
against hydroxychloroquine/chloroquine, the NIH also lacks clinical data to provide
a recommendation for or against the use of interleukin inhibitors such as anakinra,
sarilumab, siltuximab and tocilizumab.
As of this writing, these four drugs are just entering worldwide clinical trials.
While it is vitally important to find effective drugs or combinations in the treatment
of coronavirus, it is also important to do so quickly by filtering out drug
combinations with the potential for toxicity or harm.
Adverse Drug Events (ADEs) are a medical problem that can cause a wide variety
of symptoms including discomfort, pain, permanent injury or even death.
These reactions could be an allergy, overdose, a medication error, an unexpected
interaction between drugs or a reaction that exacerbates an existing disease
(health.gov, 2017).
In 1969 the US Food and Drug Administration (FDA) created a reporting system to
collect and disseminate adverse drug event data.
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This system, the FDA’s Adverse Event Reporting System (FAERS) was created
with the mission to become a centralized repository for pharmaceutical
manufacturers to monitor their post-marketed products for evidence of adverse
medical device and drug-related events. This voluntary system collects reports from
drug manufacturers, medical professionals and the general public through
MedWatch Forms FDA 3500A, 3500 and 3500B respectively. MedWatch collects
patient demographic information, current medications, the disease or diseases being
treated, symptoms, patient outcome and information about the reporter.
This information is publicly available 1 and between 2004 Quarter 1 and 2018
Quarter 2, this reporting system contained nearly 135 million records across
11 million adverse drug events. However, the FDA FAERS system lacks controls
in terms of data entry. This has led to a dirty data problem for FAERS that prevents
it from reaching its potential as a pharmacovigilance tool (Veronon et al., 2020).
Example problems include non-standardized data such as misspelled drug names,
use of multiple brand names for the same drug, abbreviations, extraneous
information, excessive punctuation/formatting, mixed capitalizations and nondescriptive data such as “unknown purposes.” Further, some records contain
nonsense data such as patient age of 7,200 years, 168,000lbs weight or symptoms
such as acupuncture, adolescence or adoption. Fortunately these are a minority of
records, however, even as a minority they pose certain problems if left untreated
(Veronin et al., 2020). As a result there are several commercial and open-source
tools that provide cleaning and simple search capabilities of FAERS data.
However, these systems have drawbacks with respect to the amount of cleaning
performed and/or the ability to form complex queries. Our motivation is to create a
pharmacovigilance system, the Tyler Adverse Drug Event System (TylerADE), to
perform data cleaning and standardization of FAERS data that can be used to
identify adverse reaction severity scores based on complex SQL queries such as
combinations of medication, demographic partitioning by age and gender as well
as adverse reaction symptoms. This system will allow researchers a finer-grained
analysis of adverse drug event data to uncover potentially unknown drug
interactions. This research has the potential to improve the efficiency of
pharmacological research by identifying potentially unknown drug interactions that
merit further clinical study and improve patient safety.
The focus of this paper is to use TylerADE on current SARS-CoV-2 drugs under
consideration by the NIH as a potential tool to identify those drug combinations
with significant adverse reactions. While this system is not meant to be a
replacement to existing drug interaction knowledge or clinical studies, we envision
it as a complimentary tool that researchers can use to fulfill the promise of FAERS.

1

https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm
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The rest of this paper is structured as follows. Section 2 is the literature review and
examines the FDA drug approval process, assessing adverse drug event causality,
FAERS data and research gaps. Section 3 presents our research questions. Section
4 is the system design and introduces the TylerADE System. Section 5 is the
experimental design. Section 6 delivers the experimental results and discussion.
Finally Section 7 provides the study conclusions, limitations and future directions.

LITERATURE REVIEW
To better understand the impacts of adverse drug events on society, we will explain
the drug approval process in the United States, examine several pharmacovigilance
systems that identify post-approval problems, investigate current systems that use
FAERS data, describe the current state of SARSCoV-2 drugs under investigation
and finish with a discourse on the research gaps found within the literature.
FDA Drug Approval Process
In the United States, the Center for Drug Evaluation and Research (CDER), a
division of the FDA, is responsible for ensuring the safety of all prescription and
over-the-counter (OTC) drugs. Although CDER does not test the drugs themselves,
they rely on testing data from both the manufacturers and the Office of Testing and
Research to determine if the drug’s health benefits outweigh the risks.
Before a new drug comes to the market, pharmaceutical manufacturers will submit
a new drug application along with evidence that it is safe and effective. CDER then
reviews the data and if the benefits outweigh the risks, the manufacturer will then
be invited to submit an investigational new drug application. After a typical 30 day
review period, the pharmaceutical company may begin Phase 1 clinical trials using
human subjects. At this stage, a several month study of 20-100 volunteers will test
dosing rates and patient side effects. If the clinical trial proves successful, the data
is sent to CDER for analysis and approval (US Dept of Health and Human Services,
2017). Approximately 70% of drugs will successfully complete this phase (US
Food & Drug Administration, 2020). Drugs will then move to Phase 2 clinical trials
where several hundred volunteers will be tested for up to two years to determine
drug efficacy and patient side effects. The results will then be forwarded to CDER
and approximately 33% of drugs will successfully complete this phase (US Food &
Drug Administration, 2020). If approved, drugs will then move to Phase 3 clinical
trials where up to several thousand volunteers will be tested for 1-4 years on
efficacy and adverse reactions with approximately 25%-30% of drugs moving to
Phase 4. At this stage only 17% of drugs are approved for use (Harper, 2020).
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This process can take an average of 15 years and cost upwards of $2 billion (Divon,
2015).
Following approval, drugs enter a post-marketing phase meaning that they are
available for use. These drugs are monitored and can either be administratively or
voluntarily withdrawn from the market. An administrative withdrawal is typically
made within a 1-6 year period following its entrance into the market (Onakpoya et
al., 2016). Drugs can also be voluntarily withdrawn from the market by the
manufacturer. One such example was Merck and Co.’s anti-inflammatory drug
Vioxx which was later found to increase the risk of heart attack and stroke
(Sibbald, 2004).
This post-marketing review of adverse drug reactions is then collected via
MedWatch and made available to manufacturers and researchers alike.
Identifying Drug Interactions
When clinical healthcare professionals are confronted with identifying interactions
from multiple medications, they will generally consult drug interaction references
to look for any known interaction potential. The Nursing Drug Handbook or online
references such as Micromedex and LexiComp can provide useful information for
known drug interactions. However, no reference can account for all interactions nor
estimate the likelihood of an adverse event occurring (Kheshti et al., 2016).
Adverse Drug Event Severity Assessment
In order to assess the impact severity of adverse drug events on patient health,
several scales have been developed. The first is a categorization section in
MedWatch where reporters can document patient outcome by selecting
predetermined boxes as shown in Figure 1.

Figure 1: MedWatch FDA Form 3500 Patient Outcomes
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While useful for reporting ADEs, it is important to note that these categories lack
explanatory descriptions and must be interpreted by the reporter whom may not be
a medical professional. This could lead to some confusion especially with how to
interpret other serious or what constitutes life-threatening.
Modified Hartwig-Siegel
The scale used in FAERS reporting is a derivative of the Modified HartwigSiegel
severity scale that categorizes adverse drug reactions into seven levels (Hartwig et
al., 1992).
• Level 1: An ADE occurred but required no change in treatment with the

suspected drug.
• Level 2: The ADE required that treatment with the suspected drug be held,

discontinued, or otherwise changed. No antidote or other treatment required. No
increase in LOS (Length of Stay).
• Level 3:The ADE required that treatment with the suspected drug be held,

discontinued, or otherwise changed, and/or an antidote or other treatment was
required. No increase in LOS.
• Level 4: (A) Any level 3 ADE which increases LOS by at least 1 day, or (B) The

ADE was the reason for admission.
• Level 5: Any level 4 ADE which requires intensive medical care.
• Level 6: The adverse reaction caused permanent harm to the patient.
• Level 7: The adverse reaction either directly or indirectly led to the death of the

patient.
The primary differences between the Modified Hartwig-Siegel and FDA Form 3500
is the latter de-emphasis of length of stay as a criteria and the absence of an option
for no change in treatment.
Hartwig Severity Assessment
One of the first attempts at quantifying severity is the Hartwig scale that examines
adverse reactions in five areas with yes/no categories. This tool calculates severity
as the sum of all yes answers (Hartwig et al., 1991).
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A. Increased monitoring needed? YES NO

•

B. Vital signs change? YES NO

•

C. Additional lab work ordered? YES NO

•

D. Treatment needed? YES NO

•

E. Increase in LOS? YES NO
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While the Hartwig scale is useful to categorize drug reaction severity, it lacks the
granularity found in the either the Modified Hartwig-Siegel or MedWatch.
Sources of ADE Data
There are several sources of ADE data including medical literature review, the
Internet and observational reports (Ventola, 2018). Medical literature review
typically involves text mining of abstracts from sources such as PubMed to identify
potential interaction signals. Pharmacovigilance systems that use the Internet will
typically monitor social media or chat forums to mine discussions for relevant drug
interactions. Observational systems rely on mining reports generated from sources
such as EHRs or adverse reports submitted to appropriate government agencies. Of
the later there are three major data sources where adverse event data can be found;
DAWN, NEDS and FAERS. All are voluntary repositories of data collected within
the United States.
The Drug Abuse Warning Network (DAWN) is a large-scale survey of medical
records used to monitor drug abuse trends nationwide (Joranson et al., 2000).
DAWN is a type of public health surveillance system to monitor drug-related visits
to hospital emergency rooms and identify trends. The eligibility criteria to enter
data in this source is any non-federal US shortstay hospital with at least one 24hour emergency department (Substance Abuse and Mental Health Services
Administration, 2019). While useful for monitoring drug abuse, the DAWN
network was discontinued in 2011 and its counterpart NEDS contains similar data.
Both DAWN and NEDS were found to be statistically similar in data composition
(Sivigny & Caces, 2018).
NEDS, the National Emergency Department Sample, is a data service from the
Healthcare Cost and Utilization Project (HCUP), sponsored by the Agency for
Healthcare Research and Quality (AHRQ), a division of the US Department of
Health and Human Services. This repository collects data from nearly 31 million
US emergency room visits annually across 953 hospitals and provides diagnostic
ICD coding, patient demographics, insurance and patient outcome.
Although extensive in scope, data records can be sparse.
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A third major data source of ADE data is FAERS. Since its creation in 1969, this
repository has undergone several transformations over the years, however, its
mission remains the same; to voluntarily collect adverse reaction reports for drugs,
medication errors and medical devices from manufacturers, medical professionals
and the general public (Toki & Ono, 2018). This massive database is publicly
available and the ADE component contains nearly 135,000,000 records spread over
seven tables from 2004 to 2018 Quarter 2 on adverse events, product complaints,
and medication error reports. Manufacturers, consumers, and health care
professionals submit voluntary reports of adverse drug interactions to the FDA.
MedWatch then collects patient demographic data, the adverse event’s impact on
patient health (e.g., disability, hospitalization, life-threatening condition or death),
product availability, suspected products or devices and information about the
reporter. Because of the lack of training and the variety of reporters contributing to
FAERS, many database fields contain a non-trivial amount of non-standardized
data (Veronon et al., 2020).
Using FAERS Data
There are several studies that use FAERS data to identify adverse reactions from
the combination of two drugs. One such study focused on data mining FAERS to
detect a statistical association between two drugs and found that reporting odds ratio
provided better signal detection of an adverse event than proportional reporting
ratio, information component and empirical Bayes geometric mean (Sakaeda et al.,
2013). A second study mined interactions between two drugs using logistic
regression and found 85% precision and 80% accuracy in predicting that an adverse
event would not occur (Ibrahim et al., 2016).
In a bid to apply pharmacovigilance to FAERS data, several notable systems have
been developed. One system manually curated the adverse effects of cardiovascular
medicines using FAERS and MEDLINE (Xu & Wang, 2014). In this study drugdisease pairs were identified by semantic markers such as <drug> CAUSE <side
effect> or <drug> TREAT <disease> from MEDLINE and compared to adverse
effects data in FAERS. This combined method found marginally better precision
and recall than FAERS alone, however, nearly 90% of the data was sacrificed to
achieve the higher accuracy.
The largest obstacle to using FAERS data is data integrity, requiring cleaning. Some
of the common problems involve drug misspellings/abbreviations (Xu & Wang,
2014), duplicate, missing and non-standardized data (Banda et al., 2016), drug trade
names vs generics (Sakaeda et al., 2013), making the use of FAERS particularly
difficult (Saragdhar et al., 2016).
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Because of the dirty data problem in FAERS, there are companies that offer paid
services for curated ADE data such as Advera Health Analytics 2, DrugLogic3 and
FDAble4. In addition to paid services there are also several freely available tools:
AERSMine, AEOLUS and OpenVigil FDA.
AERSMine
AERSMine is an ontological tool that normalizes FAERS data and aggregates drugs
and indications (Saragdhar et al., 2016). It allows researchers to search and
categorize patients based on demographics, indications, drugs and drug classes as
well as use exclusion filters. While a useful graphical tool to identify patient groups
based on apriori knowledge, the drawback is that it does not consider multiple drug
interactions. Further, the system is limited in the scope of drugs to search. For
example, the antiviral drug lopinavir only exists in conjunction with ritonavir and
cannot be queried separately.
AEOLUS
AEOLUS (Adverse Event Open Learning through Universal Standardization) is
another open-source FAERS data source that cleans raw FAERS by imputing
missing values, removing duplicate records, standardizing drug names against
OHDSI and reactions/indications against MedDRA for a standard vocabulary
(Banda et al., 2016). AEOLUS also does not evaluate multiple drug interactions.
This system reports 95% cleaning of drug-related data.
OpenVigil FDA
OpenVigil FDA is an online pharmacovigilance tool that interfaces with the
OpenFDA website and allows for easier navigation and analysis (Böhm et al.,
2016). This tool also allows for the analysis of adverse effects between two drugs.
While not entirely clear on the data cleaning aspects, OpenVigil FDA reports 88.1%
cleaning of drug-related data. Like AERSMine, OpenVigil FDA also relies on
preset drug names and does not query lopinavir by itself.

2

http://www.adverahealth.com
http://www.druglogic.com
4 http://www.fdable.com
3
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The drawbacks to AERSMine, AEOLUS, OpenVigil FDA and other systems are
that they either limit themselves to curated drugs or at most the interaction between
two drugs. A more powerful system that can investigate multiple drug combinations
as well as data related to patient demographics could be a useful tool to researchers.
SARS-CoV-2 Drugs Under Investigation
To find safe and effective treatments for SARS-CoV-2, the FDA has streamlined
the clinical investigation process to speed drug research and test for possible
treatment options. Drugs with antiviral properties as well as immunotherapy drugs
are currently under investigation. As of this writing, the NIH is currently providing
the following covid-19 treatment guidelines (National Institutes of Health, 2020).
They are not FDA approved at this time.
Antimalarials
• Hydroxychloroquine/chloroquine: Insufficient clinical data to
recommend for or against
Antiviral Nucleotide Analog
•

Remdesivir: Insufficient clinical data to recommend for or
against

Combination Treatment Antimalarial/Antibiotic
•

Hydroxychloroquine/azithromycin: Recommends Against

Combination Treatment Antivirals HIV Drugs
•

Lopinavir/ritonavir: Recommends Against

Host Modifiers/Immune-Based Therapy
•
•
•
•

Interleukin-6 Inhibitors (sarilumab, siltuximab, tocilizumab):
Insufficient clinical data to recommend for or against
Interleukin-1 Inhibitors (anakinra): Insufficient clinical data to
recommend for or against
Interferons: Recommends Against
Janus Kinase Inhibitors: Recommends Against
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Some combinations such as hydroxychloroquine/azithromycin are recommended
against because of drug safety issues rather than efficacy. If combinations of drugs
could be investigated to determine historical adverse reaction severity, clinical trials
could then focus on testing efficacy for those with lesser adverse drug reactions.
This will hopefully lead to effective treatment sooner.
Research Gaps
From our analysis of the literature, the following gaps in research emerge. First, the
process of identifying multiple drug interactions either relies on known interactions
that are documented in interaction handbooks, or rely on datasets that require a
significant investment in cleaning. Our first challenge is to develop such a system
that can produce meaningful, clean data.
Second, we didn’t find any system that focused on the patient severity risk from
multiple drug interactions. Our second challenge is to incorporate historical data of
adverse reaction severity for drugs.
Third, we did not find any systems that examined the interactions of covid-19 drugs
under investigation by the NIH.
Our aim is to build a system to produce clean data, that incorporates historical
patient severity measures from adverse drug interactions, and to study those
interactions for specific covid-19 drug combinations. Our focus is to address patient
safety and in turn prioritize clinical research to determine efficacy.

RESEARCH QUESTIONS
To address these gaps in the literature we plan to answer the following research
questions.
1. What is the adverse drug reaction safety for antiviral drug combinations?

We plan to investigate covid-19 drug combinations such as
hydroxychloroquine/chloroquine,
hydroxychloroquine/azithromycin
and
lopinavir/ritonavir with a focus on patient demographics and symptom frequency.
Answering this question will help address whether certain patient demographics
respond to antiviral combinations better than others.
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What is the adverse drug reaction safety for interleukin drug
combinations?

Applying the same framework to interleukin inhibitors of anakinra,
sarilumab, siltuximab and tocilizumab; what drug combinations are
safer than others?
3

What is the adverse drug reaction safety for drug combinations of three
covid-19 drugs?

Exploring different combinations might yield interesting results not previously
explored.

SYSTEM DESIGN
To answer these research questions we constructed the Tyler Adverse Drug Event
System (TylerADE) as shown in Figure 2.

Figure 2: TylerADE System
The TylerADE System is composed of several important areas that crossreference
multiple external data sources. The first step is to download and ETL the FAERS
data including legacy AERS data, to TylerADE.

©International Information Management Association, Inc. 2021

.

119

ISSN: 1941-6679-On-line Copy

A Data Driven Approach SARS-CoV-2 Drug Interactions

Schumaker – Veronin – Rohm – Boyett - Dixit

Drugs → Drugs Cleaning
Once the ETL process has completed, the drug data needs to pass through a series
of automated cleaning steps before it is ready for use.
This stage standardizes the data by converting all drug names to uppercase,
removing punctuation/spaces, acronym expansion, correlating drug name
information against Drugs@FDA and Micromedex Solutions (databases of current
drug names), and then removing drugs that are vague or lightly used in the corpus.
The steps are listed below.
1. Capitalize all drug names
2. Remove all leading and trailing whitespace, newline and tab characters, leading
numbers, special characters and null values
3. Expand all drug name abbreviations (e.g.; VIT B12 → VITAMIN B12)
4. Partition individual records with multiple drug names into separate records
5. Cross-reference each drug name against Drugs@FDA
6. For drugs not found in (5) convert the drug name to its generic form using
Micromedex Solutions (Truven Health Analytics, 2017)
7. Remove records with vague drug names (e.g.; painkiller, multivitamin)
8. Remove records of any drug that appears less than 30 times
Performing these steps resulted in a cleaning of 98.3% of the drugs data which
exceeds the published results of other open-source systems.
Reactions → Symptom Extraction
Patient symptom data from the Reactions table is cleaned in a similar manner.
Symptoms are made uniform through capitalization, removal of
whitespace/extraneous characters, spellchecked, and aggregated for similar
symptoms (e.g.; respiratory arrest and respiratory failure).

©International Information Management Association, Inc. 2021

.

120

ISSN: 1941-6679-On-line Copy

A Data Driven Approach SARS-CoV-2 Drug Interactions

Schumaker – Veronin – Rohm – Boyett - Dixit

Demographics → Demo. Cleaning
Demographic cleaning involves data conversions and omitting values for a minority
of data from FAERS.
1. Convert age to years
2. Omit age data for ages less than 0 or greater than 120
3. Convert gender codes other than Male or Female to Other
Outcomes → Reaction Severity
Reaction severity scores are recorded in the Outcomes table as 7 - death, 6 - lifethreatening, 5 - hospitalization, 4 - other serious, 3 - required intervention, 2 disability or permanent damage, and 1 - congenital anomaly.

EXPERIMENTAL DESIGN
For our experiment we used FAERS data from 2004 Quarter 1 through 2018
Quarter 2. This data encompasses a total of 135,276,263 records across 7 tables. A
breakdown of FAERS data is shown in Table 1.
Table 1: FAERS Data by Table (2004Q1 - 2018Q2)
Table Name
Demographics

11,094,567

Drugs
Indications
Outcomes
Reactions
Report Sources
Therapies

39,367,610
23,159,273
8,646,482
35,555,800
2,232,896
15,219,635
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Indications are the diagnoses such as rheumatoid arthritis, multiple sclerosis and
hypertension. Reactions are the observed symptoms such as nausea, death or
fatigue. Drugs are the drug names and other vital information linked to the ADE.
As shown by the number of records in the table, ADEs typically involve multiple
drugs, from a minimum of 1 to a maximum of 152. In looking further at ADEs with
the potential of multiple drug events, there are 8,552,410 records in which two or
more drugs were reported.
In terms of cleaned demographic data and gender, 6,129,171 ADE records were
female (55.2%), 3,891,117 males (35.1%) and 1,074,279 were other (9.7%).
In terms of ADEs by age ranges, Table 2 shows that most ADEs occurred for
patients between 50 and 64 years and that the elderly had the highest proportion of
reported death from ADEs.
From this data we plan to test those drug combinations under investigation for
covid-19 treatment. In particular, how safe are these various drug combinations for
differing patient demographics. Using the cleaned data from the TylerADE system,
we will perform a data-driven analysis to evaluate patient reaction severity.

EXPERIMENTAL RESULTS AND DISCUSSION
To evaluate the benefits of a data-driven approach to determine drug combination
safety, we will examine several antiviral covid-19 treatments in cluding
hydroxychloroquine/azithromycin,
hydroxychloroquine/chloroquine
and
lopinavir/ritonavir before using our technique on interleukin inhibitors anakinra,
sarilumab, siltuximab and tocilizumab, to identify the most promising combinations
for further clinical study from a drug safety perspective.
Table 2: ADEs by Age Groups
Age Group
Toddlers [0-4]
Children [5-12]
Teens [13-19]
Early Adults [20-34]
Mid-Adults [35-49]
Late Adults [50-64]
Retired Adults [65-79]
Elderly [80+]
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Research Question 1: What is the adverse drug reaction safety for antiviral drug
combinations
To answer this we investigate the antiviral drug combinations of
hydroxychloriquine/azithromycin, hydroxychloriquine/chloriquine, and
lopinavir/ritonavir.
Hydroxychloroquine and Azithromycin
Using the cleaned data in TylerADE, we analyzed the reaction severity of
hydroxychloroquine/azithromycin by performing a count of adverse reaction
outcome categories as shown in Table 3.
Table 3: Hydroxychloroquine and Azithromycin Reaction Severity
Reaction Outcome Severity Categories
Drug

1

2

3

4

5

6

7

Hydroxychloroquine

284

1,831

231

26,964

15,424

1,536

2,747

Azithromycin
Together

659
0

1,787
21

387
1

18,809
257

17,901
169

2,436
9

3,960
29

Hydroxychloroquine and azithromycin both had a similar number of adverse drug
events, 49,017 and 45,939 respectively, whereas their combination only occurred
486 times. Examining their distributions, hydroxychloroquine versus the
combination showed statistical difference in reaction severity (χ2 =43.2, df =6,
p−value = 1.06E−07). Azithromycin versus the combination showed statistical
equivalence (χ2 =8.7, df =6, p − value = 0.192), meaning that azithromycin had a
similar reaction severity profile as the combination. This is notable because
azithromycin has 45,939 adverse drug event records and 45,453 records without
hydroxychloroquine. Whereas hydroxychloroquine has similar numbers of records
and does not share the same reaction severity profile as the combination. This likely
indicates that azithromycin is the primary driver of adverse reactions in the
combination.
Focusing further, hydroxychloroquine had an average reaction severity of 4.45,
azithromycin 4.63 and taken together 4.48. Recall that a reaction severity of 4
represents other serious and 5 is hospitalization. From a drug safety perspective,
hydroxychloroquine is involved in less severe adverse drug reactions than either
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azithromycin or the combination which lends support to NIH guidelines to not
recommend this combination for covid-19 treatment.
However, other patient-related characteristics could be a factor to explore. To do
this we partitioned reaction severity outcomes of the combination of
hydroxychloroquine and azithromycin by patient age and gender as shown in Table
4.
Table 4: Hydroxychloroquine and Azithromycin by Demographic
Demographic

n

x¯

Toddlers [0-4]

21

4.52

Children [5-12]
Teens [13-19]
Early Adults [20-34]
Mid-Adults [35-49]
Late Adults [50-64]
Retired Adults [65-79]
Elderly [80+]

2
3
34
84
158
75
4

4.50
4.00
4.62
4.40
4.46
4.60
4.50

Male

106

4.62

Female
Other

369
11

4.44
4.09

From this data we noticed reaction severity was fairly uniform across age. It was
interesting to note the average reaction severity for retired adults and elderly was
4.60
and
4.50
respectively,
indicating
that
patients
receiving
hydroxychloroquine/azithromycin and had an adverse reaction required more
extensive medical care. This finding is also remarkable because it is absent the
influence of covid-19 which is also known to lengthen hospital stays. Given what
we know about covid-19 and its increased fatality rates for the elderly, the
combination hydroxychloroquine/azithromycin marginally increases risk for older
populations.
Examining differences of gender, we found that males had a higher reaction severity
to the drug combination (4.62) versus females (4.44) with differences that were
statistically different (χ2 =13.5, df = 6, p−value = 0.0362). This result is also in line
with observations that covid-19 infections disproportionately affect male patients.
Recommending a drug combination with known higher adverse reaction severity
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for males already disproportionately affected by covid-19 would only exacerbate
the problem.
We further examined the top ten patient symptoms by reaction severity for
hydroxychloroquine/azithromycin as shown in Table 5. Only symptoms with ten or
more cases are shown to reduce noise from seldom seen symptoms.
Table 5: Hydroxychloroquine and Azithromycin by Symptoms
Symptom

n

x¯

Respiratory Failure

17

5.71

Cardiac Arrest
Septic Shock
Fluid Overload
Hypotension
Tachycardia
Type 2 Diabetes Mellitus
Gastric Bypass
Sepsis
Retching

18
14
14
19
16
12
11
12
11

5.61
5.57
5.36
5.32
5.25
5.25
5.18
5.08
5.00

From this data we found that respiratory failure, cardiac arrest and septic shock
were the three most severe adverse reactions (5.71, 5.61 and 5.57 respectively).
Recall that 5 represents hospitalization and 6 is life-threatening. Symptoms also
appear to cluster around cardiopulmonary, toxicity or gastrointestinal.
Looking at the symptom data for patients 65 years and older, the most severe (5 or
higher) and frequent (n ≥ 3) adverse reaction outcomes were associated with abasia,
abdominal pain upper, anaemia, atrial fibrillation, blood glucose increased, bone
pain, chest discomfort, coagulopathy, constipation, gastrointestinal haemorrhage,
haemoptysis, haemorrhagic anaemia, heart rate increased, hyperhidrosis, malaise,
melaena, renal failure and shock haemorrhagic. Given the NIH’s recommendation
against using the combination of hydroxychloroquine/azithromycin because of
toxicity and negative clinical results, the adverse symptom data would concur with
the toxicity assessment.
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Hydroxychloroquine and Chloroquine
We further examine the reaction severity outcomes of the drug combination
hydroxychloroquine/chloroquine as shown in Table 6.

Table 6: Hydroxychloroquine and Chloroquine Reaction Severity
Reaction Outcome Severity Categories
Drug
Hydroxychloroquine

1

2

3

4

5

6

7

284

1,831

231

26,964

15,424

1,536

2,747

4
0

72
7

22
3

1,238
122

1,089
92

108
7

330
30

Chloroquine
Together

We also examined patient-related characteristics of age and gender as shown in
Table 7.

Table 7: Hydroxychloroquine and Chloroquine by Demographic

Demographic

n

Toddlers [0-4]

16

4.81

Children [5-12]
Teens [13-19]
Early Adults [20-34]
Mid-Adults [35-49]
Late Adults [50-64]
Retired Adults [65-79]
Elderly [80+]

0
0
19
60
99
19
6

–
–
4.37
4.63
4.81
4.39
5.33

Male

54

4.61

204
5

4.67
5.80

Female
Other
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From the age data there were zero reported adverse events for children [5-12] and
teens [13-19]. The data did exhibit increasing reaction severity as it relates to age.
The reaction severity for elderly was much higher (5.33) indicating that patients
with adverse reactions generally required more extensive medical care.
Examining differences in gender, we found that females had a higher reaction
severity to the drug combination (4.67) versus males (4.61), however the
differences were found to be statistically equivalent (χ2 = 10.2, df = 6, p − value =
0.118). Unlike the prior combination, hydroxychloroquine with chloroquine
showed no reaction severity differences by gender.
Looking at patient symptoms, we listed the top ten by reaction severity as shown in
Table 8. Only symptoms with ten or more cases are shown to reduce noise from
seldom seen symptoms.
Table 8: Hydroxychloroquine and Chloroquine by Symptoms
Symptom

n

x¯

Overdose

13

5.92

Cardiac Arrest
Hypokalaemia
Respiratory Failure
Myocardial Infarction
Cardiomyopathy
Cardiac Failure Congestive
Pneumonia
Muscular Weakness
Atrioventricular Block Complete

20
11
14
10
14
12
33
11
10

5.85
5.82
5.43
5.00
4.86
4.75
4.70
4.64
4.60

From this table we found that overdose, cardiac arrest and hypokalaemia were the
three most severe adverse reactions from the drug combination (5.92, 5.85 and 5.82
respectively). Symptoms appear to be mostly cardiopulmonary.
Given
the
NIH’s
neutral
stance
on
the
combination
of
hydroxychloroquine/chloroquine, the adverse event data would suggest that this
combination poses an increased risk versus hydroxychloroquine/azithromycin. This
risk is observed in a higher incidence of drug interaction severity among elderly
populations and symptoms of mostly a cardiac nature. We would recommend a
review of clinical study data to verify these results.
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Lopinavir and Ritonavir
Performing the same analysis for the drug combination lopinavir/ritonavir
we performed a count of adverse reaction outcome categories as shown in
Table 9.
Table 9: Lopinavir and Ritonavir Reaction Severity
Reaction Outcome Severity Categories
Drug

1

2

3

4

5

6

7

Lopinavir

1,919

674

232

7,678

6,689

1,205

2,272

Ritonavir
Together

3,996
1,910

1,872
665

455
230

26,059
7,521

21,964
6,587

3,506
1,198

6,372
2,233

Lopinavir had 20,669 adverse reaction events, ritonavir 64,224 and their
combination occurred 20,344 times. Examining their distributions, lopinavir versus
the combination showed statistical equivalence in reaction severity (χ2 = 0.3, df = 6,
p − value = 0.999) and showed significant overlap indicating that lopinavir and
ritonavir are commonly seen together in the data. Ritonavir versus the combination
showed statistical difference in reaction severity (χ2 = 350.1, df = 6, p − value =
1.505E −72). Focusing further, lopinavir had an average reaction severity of 4.42,
ritonavir 4.50 and taken together 4.41. Extracting adverse drug events for lopinavir
that does not include ritonavir, lopinavir’s adverse severity was 4.57, considerably
higher than the combination 4.41. Ritonavir exclusive of lopinavir was 4.54. This
was an interesting finding as both drugs taken together had a lower adverse reaction
severity than exclusive of each other.
We further examine other patient-related characteristics of age and gender as shown
in Table 10.
From the data, the drug combination disproportionately affects children [5-12] and
those 35 and older. However, the elderly were most impacted (5.15).
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Table 10: Lopinavir and Ritonavir by Demographic
Demographic

n

x¯

Toddlers [0-4]

2,365

3.71

Children [5-12]
Teens [13-19]
Early Adults [20-34]
Mid-Adults [35-49]
Late Adults [50-64]
Retired Adults [65-79]
Elderly [80+]

164
249
2,898
4,647
2,306
478
13

4.64
4.44
4.36
4.74
4.77
4.87
5.15

11,264

4.59

6,918
2,214

4.33
3.78

Male
Female
Other

Examining differences of gender, we found that males had a higher reaction severity
to the drug combination (4.59) versus females (4.33) with differences that were
statistically significant (χ2 =2,680.0, df = 6, p − value ≈ 0).
We further examined the top ten patient symptoms by reaction severity for
lopinavir/ritonavir as shown in Table 11. Only symptoms with ten or more cases
are shown to reduce noise from seldom seen symptoms.

©International Information Management Association, Inc. 2021

.

129

ISSN: 1941-6679-On-line Copy

A Data Driven Approach SARS-CoV-2 Drug Interactions

Schumaker – Veronin – Rohm – Boyett - Dixit

Table 11: Lopinavir and Ritonavir by Symptoms
Symptom

n

x¯

Suicide

20

6.85

Death Neonatal
Vomiting Projectile
Oxygen Consumption Decreased
Enterococcal Infection
Bladder Distension
Metastatic Neoplasm
Aspiration
Cardiac Arrest
Sudden Cardiac Death

72
10
14
12
10
10
17
10
18

6.19
6.10
6.00
6.00
6.00
6.00
5.94
5.90
5.89

From this data we found that suicide, neonatal death and projectile vomit were the
three most severe adverse reactions (6.85, 6.19 and 6.10 respectively). Recall that
6 represents life-threatening and 7 is death. Symptoms appear to vary and are not
restricted to limited groupings.
Looking at symptom data for patients 65 years and older, the most severe (5.5 or
higher) and frequent (n≥25) adverse reaction outcomes were associated with bone
marrow failure, circulatory collapse, hepatic failure, hepatotoxicity, multiple organ
dysfunction syndrome, pneumonia, pneumonia bacterial and sepsis. It is important
to note that no symptom was associated with an average adverse reaction severity
of 6 or higher. This would imply that in spite of the NIH recommendation against
the combination of lopinavir/ritonavir, from a patient safety perspective (and not
drug efficacy), perhaps a re-evaluation of this combination for patients 65 years and
older may be of benefit.
Answering Research Question 1
So to answer our first research question of what is the adverse drug reaction safety
for antiviral drug combinations, our analysis found hydroxychloriquine to cause
lesser adverse reactions than hydroxychloriquine/azithromycin (4.45 and 4.48
respectively). The combination was also adversely affecting retired adults and
males (4.60 and 4.62 respectively).
For hydroxychloriquine/chloriquine, the combination was more severe at 4.69. This
combination also adversely affected the elderly and females (5.33 and 4.67
respectively).
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However, for early adults and retired adults the reaction severity was much less
(4.37 and 4.39 respectively). For lopinavir/ritonavir the combination had an adverse
severity of 4.41. This combination also adversely affected the elderly (5.15) and
males (4.59). However, for toddlers the reaction severity is considerably less (3.71).
To further investigate, we analyze reaction severity by age grouping for
hydroxychloroquine/azithromycin, hydroxychloroquine/chloroquine and
lopinavir/ritonavir as shown in Figure 3.
Baseline represents all adverse drug events in the cleaned FAERS database and
we use it for comparison to several drug combinations;
hydroxychloroquine/azithromycin (H+A), hydroxychloroquine/chloroquine
(H+C) and lopinavir/ritonavir
(L+R). From this figure, the elderly [80+] are disproportionately affected more by
hydroxychloroquine/chloroquine (5.33) and lopinavir/ritonavir (5.15) versus the
baseline of all drugs (5.00). The interesting combination is
hydroxychloroquine/azithromycin that has dramatically lower reaction severity for
this population (4.50). The other combination to note is lopinavir/ritonavir for
Toddlers [0-4] that has a reduced reaction severity of 3.71.

Figure 3: Reaction Severity by Age Grouping
The NIH currently recommends against hydroxychloriquine/azithromycin, is
neutral towards hydroxychloriquine/chloriquine, and recommends against
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lopinavir/ritonavir. From our analysis of patient safety at the macro-level, all three
combinations pose risk (4.48, 4.69 and 4.41 respectively). However, from the
perspective of different age groups and genders, we observed a variety of reaction
severity outcomes with some posing much lower reaction severity. Perhaps further
study could determine if the benefits of these combinations can outweigh the risks
for specific patient populations.
Research Question 2: What is the adverse drug reaction safety for interleukin
drug combinations?
Using the cleaned data from TylerADE, we analyzed the reaction severity of
interleukins: anakinra, sarilumab, siltuximab and tocilizumab. We then performed
a count of adverse reaction outcome categories as shown in Table 12.
From the data, sarilumab and siltuximab had the fewest adverse reaction records of
18 and 38 respectively, whereas anakinra and tocilizumab had 3,680 and 34,793
respectively. Analyzing each combination for reaction severity is shown in Table
13.
Table 12: Interleukin Reaction Severity Counts
Reaction Outcome Severity Categories
Drug

1

2

3

4

5

6

7

Anakinra

21

87

12

1,589

1,314

255

402

Sarilumab
Siltuximab
Tocilizumab

0
0
47

3
0
955

0
0
15

13
17
18,160

2
10
11,527

0
6
1,667

0
5
2,422
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Table 13: Interleukin Reaction Severity Averages

From this data, sarilumab had the lowest reaction severity of 3.78 versus siltuximab
at 4.97. There were no observations of anakinra/siltuximab or sarilumab/siltuximab
in the data. It was further worth noting that interleukin combinations containing
sarilumab had lower reaction severity. For our chisquared analysis we compared
the individual drugs against each other. From a drug safety perspective it would
appear that sarilumab is the safest of the four, however, we also recognize the
limited adverse reaction data and would suggest clinical study to verify these
results.
Given the prevalence of the combination of anakinra and tocilizumab, we further
examine other patient-related characteristics of age and gender as shown in Table
14.
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Table 14: Anakinra and Tocilizumab by Demographic
Demographic

n

x¯

Toddlers [0-4]

61

4.75

Children [5-12]
Teens [13-19]
Early Adults [20-34]
Mid-Adults [35-49]
Late Adults [50-64]
Retired Adults [65-79]
Elderly [80+]

76
17
31
97
172
46
3

4.92
4.71
4.65
4.25
4.48
4.24
4.67

Male

332

4.85

Female
Other

513
53

4.35
4.85

From the data, the drug combination disproportionately affects toddlers [0-4],
children [5-12] and teens [13-19]. However, early adults [20-34] and elderly [80+]
were also observed to be adversely affected. Patients with ages between 35 and 79
appeared the least impacted.
Examining differences of gender, we found that males had a higher reaction severity
to the drug combination (4.85) versus females (4.35) with differences that were
statistically significant (χ2 = 164.0, df = 6, p − value = 8.27E −33).
We further examined the top ten patient symptoms by reaction severity for
anakinra/tocilizumab as shown in Table 15. Only symptoms with ten or more cases
are shown to reduce noise from seldom seen symptoms.
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Table 15: Anakinra and Tocilizumab by Symptoms
Symptom

n

x¯

Respiratory Failure

12

6.08

Activated Partial Thromboplastin Time Prolonged
Blood Fibrinogen Decreased
Blood Pressure Inadequately Controlled
International Normalised Ratio Increased
Pleural Effusion
Serum Ferritin Increased
Pneumocystis Jirovecii Pneumonia
Lung Infection
Infection

11
11
11
11
12
13
21
12
10

5.45
5.45
5.45
5.45
5.42
5.38
5.29
5.25
5.20

From this data we found that pulmonary-related symptoms were the most severe
adverse reactions. Anakinra and tocilizumab are both immunotherapy drugs and are
most commonly used for the treatment of rheumatoid arthritis via inflammation
reduction.
It is interesting that this drug combination would affect the lungs rather than cause
typical immunosuppressant problems such as diabetes, fatigue, neurological
impairment and gastrointestinal issues. Regardless of the source of these symptom
changes, in the context of a potential therapy for covid-19 patients, using a drug
combination with the added potential for pulmonaryrelated adverse reactions might
be problematic.
Research Question 3: What is the adverse drug reaction safety for drug
combinations of three covid-19 drugs?
To answer Research Question 3 we investigated every 3 drug combination of
antivirals and interleukins we previously studied. Many of these combinations,
especially between antivirals and interleukins, lack guidance from the NIH for their
use as covid-19 treatments. Using a data-driven approach we hope to uncover new
potential treatments that are relatively low in adverse reaction severity.
Table 16 demonstrates reaction severity outcomes for three covid-19 drug
combinations (n ≥ 10) of antivirals and interleukins. For many combinations we
observed zero entries. This absence of adverse reactions is likely due to sparse
prescriptions of the combination rather than a panacea.
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Table 16: Three Drug Combination Reaction Severity

Drug Combination

n

Azithromycin, Hydroxychloroquine and Tocilizumab
Azithromycin, Lopinavir and Ritonavir
Chloroquine, Hydroxychloroquine and Tocilizumab
Hydroxychloroquine, Lopinavir and Ritonavir

x¯

14

4.21

1,066
20
17

4.91
4.95
4.65

We call attention to the combination of azithromycin, hydroxychloroquine and
tocilizumab (4.21). This three drug combination has lower adverse reaction severity
than any of its components as shown in Table 17. The next lowest adverse reaction
severity is that of hydroxychloroquine/tocilizumab (4.24), and interestingly
enough, neither this nor the three drug combination has guidance from the NIH as
a potential covid-19 treatment.
Table 17: Three Drug Combination Reaction Severity
Drug Combination

n

Azithromycin, Hydroxychloroquine, Tocilizumab
Azithromycin, Hydroxychloroquine
Azithromycin, Tocilizumab
Hydroxychloroquine, Tocilizumab
Azithromycin
Hydroxychloroquine
Tocilizumab

x¯

14

4.21

486
88
5,494
45,939
49,017
34,793

4.48
4.78
4.24
4.63
4.45
4.58

We also examined patient-related characteristics of age and gender as shown in
Table 18.
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Table 18: Azithromycin, Hydroxychloroquine and Tocilizumab by
Demographic
Demographic

n

x¯

Toddlers [0-4]

0

–

Children [5-12]
Teens [13-19]
Early Adults [20-34]
Mid-Adults [35-49]
Late Adults [50-64]
Retired Adults [65-79]
Elderly [80+]

0
0
2
6
1
1
0

–
–
4.50
4.17
4.00
4.00
–

Male

4

4.25

10
0

4.20
–

Female
Other

From this data, the combination of azithromycin, hydroxychloroquine and
tocilizumab had adverse reactions observed in patients between 20 and 79 years of
age. Of the 14 adverse reactions observed, 11 were categorized as other serious and
3 were hospitalization. Males were also observed to have higher adverse reactions
(4.25) than females (4.20).
From a drug safety perspective, the three drug combination of azithromycin,
hydroxychloroquine and tocilizumab appears to have decreased reaction severity
and should be evaluated in a clinical trial as a potential covid-19 treatment.

CONCLUSIONS, LIMITATIONS AND FUTURE DIRECTIONS
We employed a data-driven approach to determine covid-19 drug combination
safety using a cleaned version of FDA FAERS data in TylerADE. We found that
the combination hydroxychloroquine/azithromycin had an average adverse reaction
severity of 4.48 for all populations reporting an adverse drug reaction. We further
found males more impacted and drug event severity marginally increased with
patient age. When compared against the other drug combinations,
hydroxychloroquine/azithromycin has the least adverse reactions severity on
elderly [80+] populations (4.50).
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The drug combination of hydroxychloroquine/chloroquine had an average adverse
reaction severity of 4.69 for all populations and no differences between gender.
However, elderly [80+] patients were disproportionately affected with an average
adverse reaction severity of 5.33. The drug combination of lopinavir/ritonavir had
an average adverse reaction severity of 4.41 for all populations and also
disproportionately affected males (4.59) and the elderly [80+] (5.15). It was also
interesting to note that lopinavir/ritonavir had the least adverse reaction on toddlers
[0-4] (3.71). For the interleukins, sarilumab when used in combination
demonstrated lower adverse reaction severity than other interleukin drugs in
combination. Finally, we found that the combination of azithromycin,
hydroxychloroquine and tocilizumab had low adverse reaction severity (4.21) and
from a drug safety perspective shows potential as a covid19 treatment option.
There are several limitations to this study. First, this study relies on adverse drug
event reports reported to the FDA. We recognize that not all adverse drug events
will be reported or there could be a skew towards reporting only the most severe
adverse events. To accommodate this we only made comparisons within the
datasets between drugs. Second, we rely on the reported data to be accurate and
complete. We employed a painstaking process of data cleaning to ensure the
reliability of data and omitted it when necessary. Third, although there are large
numbers of adverse drug events on total, some drug combinations have few records
and made comparison difficult. We did include the number of records in these
situations so that readers can make an informed decision. Fourth, the purpose of
this study is to evaluate drug combination safety from historical records. It is meant
as a prelude to clinical trial data. Drug efficacy is not considered. Fifth, dosing,
manufacturer and route of administered drugs was not considered.
Only the presence/absence of the drug was evaluated. While we recognize their
importance, we felt partitioning to this level of detail would dilute the data to be of
little comparative value and felt it best for clinical trial data to address those
concerns.
Future directions include investigating the safety of other drug combinations that
show promise such as other antivirals and interleukins. Further partitioning of data
based on patient ethnicity or pre-existing conditions might also prove insightful.
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